SEC Filing Summary: PerkinElmer, Inc. Form 10-Q
Entity and period: The supplied filing identifies the registrant as PerkinElmer, Inc., not Revvity, Inc. It reports the quarter and six months ended July 4, 2010, with comparisons to July 5, 2009. The filing is unaudited.
Business context and reporting period
PerkinElmer operated through Human Health and Environmental Health segments, serving diagnostics, research, environmental, safety, security, industrial, and laboratory-services markets. Management reported signs of recovery across many markets, alongside continued customer budget constraints in parts of diagnostics and research.
Financial performance
| Metric | Q2 2010 | Q2 2009 | Six months 2010 | Six months 2009 |
|---|---|---|---|---|
| Sales | $497.8 million | $438.3 million | $962.9 million | $873.4 million |
| Operating income, continuing operations | $42.6 million | $38.2 million | $82.1 million | $63.5 million |
| Net income, continuing operations | $53.9 million | $23.2 million | $80.0 million | $37.9 million |
| Reported net income | $57.6 million | $21.5 million | $82.0 million | $32.1 million |
| Diluted EPS | $0.49 | $0.18 | $0.69 | $0.28 |
- Q2 sales rose 14%; six-month sales rose 10%. Q2 growth included an approximately 2% foreign-exchange headwind and 2% contribution from acquisitions.
- Q2 gross margin was 42.7%, down about 20 basis points year over year; six-month gross margin was 42.7%, down about 40 basis points. Management attributed pressure mainly to product mix, partly offset by productivity and cost containment.
- Q2 operating margin was approximately 8.6%, versus 8.7% a year earlier; six-month operating margin improved to approximately 8.5% from 7.3%.
- Segment sales and operating income: Human Health Q2 sales were $197.5 million and operating income $25.8 million, up 7% in each; Environmental Health sales were $300.4 million, up 19%, and operating income was $24.8 million, up 9%. For the six months, segment sales grew 7% and 13%, respectively.
- Continuing-operations operating cash flow was $121.1 million for the first half, versus $58.2 million. Capital expenditures were $18.5 million; investing cash outflow was $135.5 million, including substantial acquisition spending.
- Cash and equivalents were $215.7 million at July 4, compared with $179.7 million at January 3. Current assets were $923.9 million and current liabilities $513.9 million.
- Debt included $468.0 million drawn on the revolving facility and $150.0 million of 6% senior notes; the balance sheet reported $620.3 million of total short- and long-term debt. The $650 million revolver had $167 million available, including the effect of letters of credit. The company reported covenant compliance.
- Quarterly dividends were $0.07 per share; first-half dividends paid totaled $16.5 million.
Material changes and unusual items
- Reported earnings benefited materially from a $25.6 million pretax gain on remeasurement of PerkinElmer’s previously held interest when it acquired the remaining 50% of its ICPMS joint venture. This gain was recorded in interest and other income, not operating income.
- The lower effective tax rate—15.8% for Q2 and 20.1% for the first half, versus 31.7% and 30.4% in the comparable periods—reflected the ICPMS gain and favorable tax-audit settlements. Q2 included $1.9 million of tax benefits from remeasurements, audit closures, and other discrete items.
- Q2 restructuring charges totaled $9.9 million, associated with workforce reductions and facility closure; 115 employees were affected. The company also recorded a $3.4 million gain on sale of a fire-damaged Boston facility and a $4.6 million pretax gain on the Photoflash business sale.
- May 2010 acquisitions included Signature Genomic Laboratories for $90 million cash and the remaining ICPMS joint-venture interest for $35 million cash, among other consideration. After quarter-end, on July 30, the company acquired VisEn Medical for $29.8 million cash, including escrowed amounts.
- Goodwill was $1.525 billion at quarter-end, up from $1.463 billion at fiscal year-end, principally reflecting acquisitions and currency translation.
Outlook, risks, and contingencies
- Management described improved demand in many markets and expected internal cash generation to fund operating expenses, capital spending, smaller acquisitions, interest, and dividends. The filing provides no specific revenue or earnings guidance.
- Management cited continued constraints in pharmaceutical and neonatal-lab budgets, delayed research orders, and uncertainty around government funding. It also noted product-mix pressure, increased pension costs, foreign-exchange exposure, and possible additional pension funding of up to $11.5 million outside the U.S. and up to $30 million for the U.S. plan during fiscal 2010.
- Key disclosed risks include economic and funding weakness, quarterly order volatility, competition and product-development execution, acquisition integration, regulatory and healthcare compliance, foreign currency and international operations, supplier disruptions, debt covenants and access to credit, and potential impairment of goodwill and intangible assets.
- Environmental liabilities were accrued at $5.9 million. The long-running Enzo patent and commercial dispute remained stayed pending further proceedings in a related case; management said it did not expect a material adverse financial effect. Other legal matters were described as uncertain but not expected to be material based on information then available.
- The company stated that disclosure controls were effective as of July 4, 2010 and reported no material quarterly change in internal control over financial reporting.
Important facts for investors to verify
- Confirm that this PerkinElmer filing—not a Revvity filing—is the intended document; the company name in the request metadata does not match the registrant in the supplied text.
- Separate recurring operating performance from the $25.6 million ICPMS remeasurement gain, the tax benefits, and disposition gains when assessing earnings growth.
- Review acquisition purchase-price allocations, integration progress, and the impact of the July 30 VisEn acquisition, which occurred after the reporting date.
- Track revolver utilization, floating-rate exposure, covenant headroom, pension funding needs, and the planned timing of restructuring payments.
- Assess whether reported sales recovery and cash generation persist, particularly given working-capital investment and ongoing customer budget constraints.